Peptides - Metabolic
Retatrutide
Triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors
Dosage
Starting 0.5mg, titrate up weekly
Results
4-8 weeks
Frequency
Weekly
Cost
$200-400/month
Estimated monthly
$200-400
About Retatrutide
Retatrutide is a next-generation triple-agonist peptide that targets GLP-1, GIP, and glucagon receptors simultaneously. This unique triple action provides powerful metabolic benefits, with clinical trials showing substantial weight loss. It represents the cutting edge of metabolic peptide therapy, building on the success of earlier GLP-1 medications.
Administration
Method
Subcutaneous injection
Timing
AM
Food
Any time
Key Benefits
- Significant weight loss potential
- Improved glycemic control
- Reduced appetite
- Enhanced metabolic health
- Triple receptor activity
Stacks Well With
Important Considerations
- • MEN2
- • Thyroid cancer history
- • Pancreatitis
- • Pregnancy
Additional Notes
- • Start low and titrate slowly
- • May cause GI side effects initially
Research & Studies
Retatrutide: Triple-Agonist Phase 2 Trial Results
2023·Clinical Trial
GLP-1/GIP/Glucagon Tri-Agonists: Metabolic Effects
2022·Review
Research provided for educational purposes. Always consult a healthcare provider.